Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Source: View publication →
In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4 mg significantly reduced the risk of a composite kidney endpoint by 22% and slowed eGFR decline in non-diabetic adults with overweight or obesity and established cardiovascular disease.
Key Findings
Study Design
Study Limitations
Clinical Significance
This analysis establishes that the cardio-metabolic benefits of GLP-1 receptor agonists extend to renal protection even in the absence of diabetes. For patients with obesity and cardiovascular disease, semaglutide offers a disease-modifying approach that mitigates obesity-associated chronic kidney disease progression, emphasizing the renoprotective value of metabolic and weight optimization.
Historical Context
Historically, major trials demonstrating pharmacological renal protection have focused almost exclusively on populations with diabetic kidney disease (e.g., using RAAS inhibitors, SGLT2 inhibitors, or non-steroidal MRAs). While the primary SELECT trial broke ground by showing semaglutide reduced major adverse cardiovascular events (MACE) in a non-diabetic obese population, this secondary analysis bridged a critical gap in nephrology. Released concurrently with the FLOW trial—which proved primary kidney benefits of semaglutide in diabetic kidney disease—this SELECT analysis confirms that GLP-1 receptor agonists exert broad renoprotective effects that are at least partially independent of glucose-lowering.
Guided Discussion
High-yield insights from every perspective
Given that the patients in the SELECT trial were non-diabetic, what are the proposed mechanisms by which semaglutide confers kidney protection and slows eGFR decline independent of glycemic control?
Key Response
This question tests foundational knowledge of the pleiotropic effects of GLP-1 receptor agonists. In the absence of hyperglycemia, semaglutide's nephroprotective mechanisms include the reduction of systemic inflammation, improvement in endothelial function, and reduction of obesity-related glomerular hyperfiltration through weight loss. Additionally, GLP-1 RAs may inhibit proximal tubular sodium reabsorption via NHE3, leading to increased macula densa sodium delivery and afferent arteriolar vasoconstriction via tubuloglomerular feedback, which reduces intraglomerular pressure.
A 55-year-old patient with obesity (BMI 34), a prior myocardial infarction, and no diabetes presents with an eGFR of 55 mL/min/1.73m2. Based on the SELECT trial findings, how would you incorporate semaglutide into their management, and what specific clinical monitoring would you prioritize?
Key Response
This addresses clinical application and patient management. The resident should recognize that semaglutide 2.4 mg is indicated for secondary CV prevention in this patient, with the added benefit of slowing eGFR decline as per SELECT. Management involves starting semaglutide while actively monitoring for gastrointestinal side effects (nausea, vomiting, diarrhea) that could lead to acute volume depletion and acute kidney injury, a critical consideration in a patient with pre-existing stage 3 CKD.
How does the initial eGFR trajectory observed with semaglutide in the SELECT population compare to the hemodynamic 'dip' typically seen with SGLT2 inhibitors, and how should this influence the strategy for combining these agents in non-diabetic patients with structural kidney disease?
Key Response
This requires nuanced subspecialty knowledge. Fellows must differentiate between the pronounced acute hemodynamic eGFR dip of SGLT2 inhibitors (driven by strong afferent vasoconstriction) and the eGFR trajectory of semaglutide, which typically shows a much milder or absent acute dip but a gradual slowing of long-term decline. Understanding these distinct profiles helps nephrology/cardiology fellows safely sequence or combine these disease-modifying therapies without causing alarming acute drops in kidney function.
The SELECT trial expands the nephroprotective role of GLP-1 RAs to a non-diabetic population. How does this shift our historical paradigm of treating 'obesity-related glomerulopathy', and how do we prioritize GLP-1 RAs versus RAAS blockade in a normotensive patient with severe obesity and declining eGFR?
Key Response
This explores practice-changing implications. Historically, RAAS inhibition was the primary pharmacological tool used to blunt hyperfiltration in obesity-related CKD, even in normotensive patients. The SELECT data suggests that directly targeting the underlying adiposity and systemic inflammation with semaglutide offers a profound disease-modifying approach, prompting attendings to reconsider the hierarchy of CKD therapies and potentially position GLP-1 RAs earlier in the treatment algorithm for obesity-related kidney disease.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Because the kidney outcomes in the SELECT trial were a pre-specified secondary analysis rather than the primary endpoint, how does the hierarchical testing strategy and the low event rate of 'hard' kidney endpoints (like kidney failure) affect the statistical power and interpretation of the 22% risk reduction in the composite kidney endpoint?
Key Response
This targets advanced research methodology. A PhD-level critique must evaluate whether the 22% reduction in the composite endpoint was driven predominantly by less severe surrogate markers (like eGFR decline or new-onset macroalbuminuria) rather than hard endpoints like ESKD. Because it is a secondary analysis in a population with generally preserved baseline kidney function, the study may lack statistical power for isolated hard kidney outcomes, necessitating caution when interpreting the clinical weight of the composite risk reduction.
As an editor reviewing this manuscript, how would you challenge the authors to address the extent to which the observed kidney benefits are mediated directly by semaglutide versus indirectly through the substantial weight loss achieved, and why is this methodological distinction critical for the field?
Key Response
This focuses on critical appraisal and threats to validity. A rigorous reviewer would demand a formal mediation analysis to separate the drug's direct renal effects (e.g., anti-inflammatory, endothelial) from the hemodynamic benefits of losing substantial body weight. If the benefit is entirely weight-mediated, any potent weight loss intervention (like bariatric surgery or tirzepatide) might achieve similar outcomes; if direct, it establishes semaglutide as uniquely nephroprotective independent of weight.
Current KDIGO guidelines strongly recommend GLP-1 RAs for patients with T2D and CKD. Based on the SELECT secondary analysis, should guidelines be updated to grant a specific recommendation for GLP-1 RAs to prevent kidney function decline in non-diabetic CKD patients with obesity, or is a dedicated primary kidney outcome trial required first?
Key Response
This explores evidence grading and guideline formulation. While SELECT is a landmark trial for CV outcomes, the kidney endpoint was secondary. Guideline committees typically require a primary outcome trial (such as the FLOW trial, though FLOW was conducted in T2D) to issue a definitive Class I recommendation for CKD progression. The committee must debate whether a highly significant secondary outcome in a massive CV trial is sufficient evidence to update KDIGO or AHA/ACC guidelines to formally recommend semaglutide for renoprotection in non-diabetic obesity.
Clinical Landscape
Noteworthy Related Trials
SUSTAIN 6
Tested
Semaglutide 0.5mg or 1.0mg weekly
Population
T2DM patients with high CV risk
Comparator
Placebo
Endpoint
3-point MACE
EMPA-KIDNEY
Tested
Empagliflozin 10mg daily
Population
Patients with chronic kidney disease (with or without T2DM)
Comparator
Placebo
Endpoint
Composite of kidney disease progression or cardiovascular death
FLOW Trial
Tested
Semaglutide 1.0mg weekly
Population
T2DM patients with chronic kidney disease
Comparator
Placebo
Endpoint
Composite of major kidney disease events and cardiovascular death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis